Piper Jaffray Remains Sidelined on Celgene (CELG) Following Phase 3 AUGMENT Disclosure
Tweet Send to a Friend
Piper Jaffray reiterated a Neutral rating and $95.00 price target on Celgene (NASDAQ: CELG) following the company's disclosure that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
